BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nucala (Mepolizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nucala (Mepolizumab)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05902325-1437@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nucala (Mepolizumab): Phase 4 readout est. (NCT05902325)
DESCRIPTION:Nucala (Mepolizumab)\, phase 4.\nStudy: Identifying Predictors 
 Of Response To Mepolizumab In CRSwNP\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mepolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5902325
URL:https://assetmemo.bio/drug/mepolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05923047-1437@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Nucala (Mepolizumab): Phase 4 readout est. (NCT05923047)
DESCRIPTION:Nucala (Mepolizumab)\, phase 4.\nStudy: Mepolizumab and In-offi
 ce Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). A Thre
 e Arm Study.\nEstimated primary completion: 1 January 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/mepolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05923047
URL:https://assetmemo.bio/drug/mepolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07749001-1437@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Nucala (Mepolizumab): Phase 4 readout est. (NCT07749001)
DESCRIPTION:Nucala (Mepolizumab)\, phase 4\, Chronic Obstructive Pulmonary 
 Disease.\nStudy: Airway Dysfunction\, Occlusions and Remodeling: COPD Pati
 ents and Mepolizumab\nEstimated primary completion: 28 February 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/mepolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07749001
URL:https://assetmemo.bio/drug/mepolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200336-1437@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20291010
DTEND;VALUE=DATE:20291011
SUMMARY:Nucala (Mepolizumab): Phase 4 readout est. (NCT07200336)
DESCRIPTION:Nucala (Mepolizumab)\, phase 4.\nStudy: Anti-IL-5 Therapy With 
 Simple Polypectomy Versus Extended Endoscopic Sinus Surgery for CRSwNP\nEs
 timated primary completion: 10 October 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/mepolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07200336
URL:https://assetmemo.bio/drug/mepolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06501807-1437@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20340902
DTEND;VALUE=DATE:20340903
SUMMARY:Nucala (Mepolizumab): Phase na readout est. (NCT06501807)
DESCRIPTION:Nucala (Mepolizumab)\, phase na.\nStudy: BIOlogics in Severe Na
 sal POlyposis SurvEy.: a French Registry\nEstimated primary completion: 2 
 September 2034. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mepol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06501807
URL:https://assetmemo.bio/drug/mepolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
